3Kochenderfer JN, Wilson WH, Rosenberg SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. Blood ,2010,116:4099- 4102.
4Porter DL, Levine BL, June C H, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl J Med,2011,365 :725-733.
5Grupp SA, Kalos M, Barrett D,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med,2013,368:1509- 1518.
6Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD 19- targeted T cells cause regressionof malignancy persisting after allogeneic hematopoietic stem cell transplantation[J]. Blood ,2013,122:4129-4139.
7Brentjens R J, Davila ML, Riviere I, et ah CD 19-targeted T ceils rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia[J]. Sci Transl/fled ,2013,5 : 177ra38.
8Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28zCAR T cell therapy in B cell acute lymphohlastic leukemia[j]. Sci Transl Med, 2014,6 : 224ra225.
9Kochenderfer JN, Dudley ME, Rosenberg SA, et al. Chemotherapy-refrac- tory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an Anti CD19 Chi- meric Antigen Receptor[J]. J Clin Onco1,2015,33:540-549.
10Wang Y,Zhang WY, Han WD, et al. Effective response and delayed toxici- ties of refractory advanced diffuse large B-cell lymphoma treated.by CD20- directed chimeric antigen receptor-modified T cells[J]. Clin Immunol,20 l g, 155 : 160-175.
8Schmidt-Wolf IG,Negrin RS,Kiem HP,et al.Use of a SCID Mouse/Human lymphoma model to evaluate cytokine.Induced killer cells with potent antitumor cell activity[J].Exp Med,1991,174:139.
9Gunzer M,Janich S,Varga G,et al.Dendritic cells and tumor immunity[J].Semin Immunol,2001,13(5):291-302.
4Jing-Ting Jiang, Chang-Ping Wu, Lu-Jun Chen, Xiao Zheng, Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China Yi-Bei Zhu, Jing Sun, Xue-Guang Zhang, Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China Yue-Ping Shen, Wen-Xiang Wei, Department of Medicine, Soochow University, Suzhou 215123, Jiangsu Province, China Bin-Feng Lu, Department of Immunology, University of Pitts- burgh School of Medicine, Pittsburgh, PA 15261, United States.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J].World Journal of Gastroenterology,2010,16(48):6155-6162. 被引量：82
5Singh H, Figliola M J, Dawson MJ ,et al. Manufacture of clin- ical- grade CDI9- specific T cells stably expressing chim- eric antigen receptor using sleeping beauty system and artifi- cial antigen presenting cell [ J ]. PLoS One, 2013,8 (5) : e64138.
6Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer[ J ]. Annu Rev Immuno1,2007,25:243 - 265.
7Stephen JS, Jakub S, Sunita DN, et al. Sustained remissions following chimeric antigen receptor modified T cells direct- ed against CD19 (CTL019)in patients with relapsed or re- fractory CD19 + lymphomas [ R ]. Orlando : Orange County Convention Center,2015.
8Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T - cell - engaging antibody blinatumomab ofchemotherapy -refractory minimal residual disease in B - lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia -free survival [J]. J Clin Oncol,2011,29(18) :2493 -2498.
9Lee DW, Kochenderfer JN, Stetler - Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young aduhs: a phase 1 dose - escalation trial [ J ]. Lancet, 2015, 385 (9967) :517 - 528.
10Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen re- ceptor- modified T cells for acute lymphoid leukemia [ J ]. N Engl J Med,2013,368(16) :1509 -1518.
